Request Deal Involvement
Royalty Pharma completed the acquisition of Theravance Respiratory Company from Innoviva for $1.61bn.
Identify your role
Select the side you represented in this transaction, and provide your current job title.
Service Providers
legal advisors
Jones Day
legal advisors
Goodwin Procter
legal advisors
Maiwald
financial advisors
Torreya Capital
pr advisors
FGS Global
financial advisors
Moelis & Co
legal advisors
Willkie Farr & Gallagher
pr advisors
Argot Partners
financial advisors
MTS Securities
legal advisors to financial advisors
Fried Frank Harris Shriver & Jacobson
financial advisors
Evercore
legal advisors
Skadden Arps Slate Meagher & Flom
or
Principals
bidder
ROYALTY PHARMA
target
THERAVANCE RESPIRATORY COMPANY
vendor
INNOVIVA INC
Principals or Service Provider not listed?Add missing Service Provider or Principal
Enter your Job Title on this deal
This title will appear on your profile next to this deal involvement.
To help us verify your involvement, please include links to any relevant publications that mention you or your company's role in this deal:
All rights reserved. Copyright © 2025 Datasite